Ultrasep ES Pharm-RP8EA is a silica-based HPLC column with an enhanced alkyl-bonded C8 phase and advanced endcapping technology. This bonding chemistry provides balanced hydrophobic retention, reduced silanol interactions, and excellent stability under routine and demanding pharmaceutical conditions.
Compared to standard C8 or C18 phases, Pharm-RP8EA combines faster elution with reliable selectivity, making it ideal for the analysis of moderately hydrophobic compounds, impurity profiling, and stability-indicating assays. Its optimized endcapping ensures sharp peak shapes and reproducibility even for challenging basic analytes.
Ultrasep ES Pharm-RP8EA delivers enhanced C8 performance with advanced endcapping – the dependable choice for pharmaceutical laboratories requiring robust and reproducible HPLC separations.
Silica-based stationary phase with enhanced alkyl-bonded C8 chemistry
Advanced endcapping for minimized silanol interactions
Balanced hydrophobic retention with faster elution than C18 phases
High stability, reproducibility, and long column lifetime
Available particle size: 5 µm
Pharmaceutical impurity profiling and stability studies
Analysis of moderately hydrophobic drugs with reproducible peak shapes
Method development requiring complementary selectivity to C18 phases
Routine quality control and regulatory testing
| Particle Size |
|
|---|---|
| Pore Size | 100 Å |
| Particle Type | |
| Separation Mode | |
| USP Code | |
| Endcapping | Yes |
| pH Range | 2 - 8 |
| Phase | Material Number |
|---|---|
| Ultrasep ES Pharm-RP8EA, 5 µm | u15.p8ea. |